RT Journal Article
SR Electronic
T1 Indications and Outcome of Intravitreal Bevacizumab Injection in a Community Eye Hospital, Nepal
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.31.24311307
DO 10.1101/2024.07.31.24311307
A1 Thakali, Sunil
A1 Shrestha, Mohini
A1 Gauchan, Aleena
A1 Gurung, Hom Bahadur
A1 Poudel, Manish
YR 2024
UL http://medrxiv.org/content/early/2024/08/01/2024.07.31.24311307.abstract
AB Intravitreal bevacizumab(IVB) injection, is a humanized monoclonal antibody that has been in use for the treatment of retinal diseases, very cheaply, especially for developing countries like Nepal. This is a retrospective study designed to evaluate the indications and outcomes of IVB at Hetauda Community Eye Hospital from 2019 to 2022. In this study, among 247 patients including 260 eyes with a follow-up rate of 221 patients involving 234 eyes, the mean patient age was 64.4 years, with male predominance of 56.1%. Thus, IVB was used principally in the treatment of diabetic retinopathy, neovascular age-related macular degeneration, and branch retinal vein occlusion. The results indicated significant improvements in central macular thickness and visual acuity with respect to diabetic retinopathy, nAMD, and BRVO. The study thus puts forth the effectiveness of IVB in improving visual outcomes and reducing CMT in a resource-constrained setting; hence, its use should be implemented as a viable treatment option within such an environment.Competing Interest StatementThe authors have declared no competing interest.Funding StatementnoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Review Board of Tilganga Institute of Ophthalmology, approval number 18/2023I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data supporting the findings of this study are available from Hetauda Community Eye Hospital. Due to privacy and confidentiality concerns, access to the data is restricted. Researchers interested in accessing the data should contact the corresponding author for further information and to discuss potential data sharing arrangements